To battle those disruptions, AbbVie, maker of three migraine treatment options, launched a contest this year to provide support for people whose migraines create obstacles in reaching their ...

AbbVie stock (NYSE: ABBV) was down 12% on Monday, November 11, after the company announced that two mid-stage clinical trials of its drug Emraclidine to treat schizophrenia failed to meet their ...

AbbVie’s ABBV stock declined almost 11% in the past month, mainly due to a recent pipeline setback. In November, AbbVie announced that two registration-enabling phase II studies on emraclidine ...

Emraclidine was part of AbbVie's acquisition of Cerevel last year, which also included Tavapadon, which reported positive Phase 3 data. Bristol's Cobenfy is now poised to dominate the ...

For AbbVie, (NYSE: ABBV) it looks like some celebration is in order, because it just resolved one of its most pressing issues of the past few years. Here's how this drugmaker proved the bears ...

AbbVie has broken ground on a new $223 million expansion of its biologics manufacturing facility in Singapore, creating around 100 new jobs. The new investment will grow its workforce at the site ...

AbbVie has ended speculation about what it will charge for its newly-approved Vuity therapy for presbyopia, a sight condition characterised by difficulty in focusing on near objects. The company ...

Based on 19 Wall Street analysts offering 12 month price targets forAbbVie Inc - Dist in the last 3 months.

DiveWire guarantees visibility for your news announcements through instant distribution to BioPharma Dive’s audience and its 153,500 newsletter subscribers for 21 days.